| Ticker Details |
|
BioXcel Therapeutics, Inc.
|
| IPO Date: |
March 5, 2018 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$25.16M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.62 | 4.76%
|
| Avg Daily Range (30 D): |
$0.05 | 4.88%
|
| Avg Daily Range (90 D): |
$0.05 | 4.71%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.03M |
| Avg Daily Volume (30 D): |
.78M |
| Avg Daily Volume (90 D): |
.84M |
| Trade Size |
| Avg Trade Size (Sh.): |
159 |
| Avg Trade Size (Sh.) (30 D): |
293 |
| Avg Trade Size (Sh.) (90 D): |
318 |
| Institutional Trades |
| Total Institutional Trades: |
908 |
| Avg Institutional Trade: |
$1.45M |
| Avg Institutional Trade (30 D): |
$.87M |
| Avg Institutional Trade (90 D): |
$.87M |
| Avg Institutional Trade Volume: |
.01M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.56M |
| Avg Closing Trade (30 D): |
$.87M |
| Avg Closing Trade (90 D): |
$.87M |
| Avg Closing Volume: |
4.6K |
|
|
| News |
Jul 21, 2026 @ 9:00 PM
[Latest] Global AI in Drug Repurposing Market Size...
Source: Healthcare Foresights
|
Mar 23, 2026 @ 12:00 PM
Levi & Korsinsky, LLP Announces Proposed Class Act...
Source: Levi & Korsinsky, Llp
|
Mar 10, 2026 @ 6:36 PM
BioXcel Therapeutics Announces Approximately $8.0 ...
Source: Bioxcel Therapeutics, Inc.
|
Oct 13, 2025 @ 11:00 AM
BioXcel Therapeutics to Ring Nasdaq Closing Bell o...
Source: Vimal Mehta, Ph.D.
|
Sep 18, 2025 @ 11:00 AM
BioXcel Therapeutics Regains Compliance with Nasda...
Source: Bioxcel Therapeutics, Inc.
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-2.55
|
$-.49
|
$-.54
|
|
Diluted EPS
|
$-2.55
|
$-.49
|
$-.54
|
|
Revenue
|
$.74M
|
$.18M
|
$.21M
|
|
Gross Profit
|
$.39M
|
$.16M
|
$-.08M
|
|
Net Income / Loss
|
$-70.86M
|
$-14.71M
|
$-12.69M
|
|
Operating Income / Loss
|
$-44.93M
|
$-10.19M
|
$-10.22M
|
|
Cost of Revenue
|
$.35M
|
$.02M
|
$.28M
|
|
Net Cash Flow
|
$M
|
$M
|
$M
|
|
PE Ratio
|
|
|
|
|
|
|
